There have been only a few studies attempting to develop a scoring system for poor outcomes of CBF‐AML (eg, relapse and disease‐free survival [DFS]).6, 8 The relative rarity of CBF‐AML (approximately 15%‐20% of AML cases) in adults9 and its relatively good prognosis may have limited these efforts. This evidence concerns the gene CEBPZ and acute myeloid leukemia.